Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Her-2 Negative Breast Cancer × fluzoparib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Triple Negative Breast Neoplasms 4 Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Her-2 Negative Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Female Breast Cancer Patients 1 Breast Cancer Metastatic 1 Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

fluzoparib 1 camrelizumab 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05761470 2023-03-09

IMPARP

First Affiliated Hospital, Sun Yat-Sen University

Phase 2 Recruiting

Her-2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡